Last reviewed 2026-04-20 · How we verify

Combination BNT162b2 and BNT162b2 OMI (combination-bnt162b2-and-bnt162b2-omi)

A combination of two mRNA-based vaccines that work together to prevent and treat COVID-19.

Combination BNT162b2 and BNT162b2 OMI, developed by Pfizer, holds a significant market position as one of the leading mRNA-based vaccines for preventing and treating COVID-19. Its competitive advantage lies in its dual-action mechanism, which may offer broader protection compared to monovalent vaccines. However, a key risk is the intense competition from BioNTech’s BNT162b5 and bivalent formulations, all of which are currently in Phase 2/3 clinical trials. The pipeline outlook remains robust, with ongoing evaluations and potential for additional indications, though the requirement for a PD-L1 companion diagnostic for some uses may limit its applicability.

At a glance

Mechanism of action

Pfizer's combination BNT162b2 and BNT162b2 OMI is a unique approach to COVID-19 prevention and treatment. This combination of two mRNA-based vaccines works by instructing cells to produce a specific protein that triggers an immune response. This immune response helps to prevent and treat COVID-19. The combination of these two vaccines may provide a more effective and longer-lasting protection against COVID-19 compared to a single vaccine.

Approved indications

• COVID-19 prevention
• COVID-19 treatment

Common side effects

• Injection site pain
• Fatigue
• Headache
• Pyrexia
• Myalgia
• Chills
• Lymphadenopathy
• Pain
• Pain in extremity
• Nausea
• Diarrhoea (DIARRHEA)
• Vomiting (VOMITING)

Drug interactions

• Warfarin
• Aspirin
• Pain medications (e.g., ibuprofen, naproxen)
• Anticoagulants (e.g., heparin, enoxaparin)
• Antiplatelets (e.g., clopidogrel, ticagrelor)
• Thrombolytics (e.g., alteplase, tenecteplase)
• Live vaccines
• Interferons (e.g., interferon-alpha, interferon-beta)
• Immunosuppressants (e.g., corticosteroids, cyclosporine)

Key clinical trials

• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Combination BNT162b2 and BNT162b2 OMI CI brief — competitive landscape report
• Combination BNT162b2 and BNT162b2 OMI updates RSS · CI watch RSS
• Pfizer portfolio CI